What the research examined
LEADER compared liraglutide with placebo in people with type 2 diabetes at high cardiovascular risk. The trial reported a lower rate of its primary composite cardiovascular outcome. Gastrointestinal events were among the reasons participants discontinued the study medicine.
How to interpret the findings
A composite combines different events; its result does not mean every individual component showed the same effect. The findings concern a defined medicine and high-risk population and should not be generalized to every peptide or GLP-1-related compound.
Research literature
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The New England journal of medicine · 2016 · PMID 27295427
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.